scholarly journals Current Treatment Regimen for Breast Cancer

2020 ◽  
Vol 4 (7) ◽  
pp. 29-31
Author(s):  
Prathyoosh C ◽  
Karukakulam Sandra Dominic
Keyword(s):  
Breast Cancer ◽  
Treatment Regimen ◽  
Current Treatment ◽  
Current Treatment Regimen

Mixed metabolic response on PET/CT in patients with metastatic breast cancer as an early predictor of disease progression.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11522-e11522
Author(s):  
Urmi Sen ◽  
Huichung Tina Ling ◽  
Akansha Chhabra ◽  
Kent P Friedman ◽  
Amy Tiersten
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Disease Progression ◽  
Treatment Regimen ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Current Treatment ◽  
Pet Ct ◽  
Current Treatment Regimen ◽  
Pet Ct Scan

e11522 Background: It has been observed that patients undergoing systemic therapy for metastatic breast cancer (MBC) may demonstrate a mixed metabolic treatment response on FDG PET (MMTR) while maintaining stable disease on CT (SDCT). The purpose of this study is to determine (1) the clinical outcome of MBC patients demonstrating MMTR+SDCT who were maintained on the same treatment regimen and (2) the behavior of oncologists when faced with a report of MMTR+SDCT. Methods: All FDG PET/CT scan reports performed at one institution between 2006-2011 were searched and studies describing a MMTR also containing the term “breast cancer” were identified. MBC patients without other active malignancies were extracted from the search and scans were re-analyzed. MMTR was defined as a PET/CT scan demonstrating a minimum of 2 lesions with a SUVmax change of +25% or more combined with at least 2 lesions demonstrating a SUVmax change of -25% or more. The subset of patients with MMTR+SDCT (by anatomical RECIST criteria) who were maintained on their current treatment regimen was further examined to identify time to progression (TTP). Results: Thirty-two cases were identified that demonstrated MMTR+SDCT in metastatic breast cancer patients. No change in therapy occurred within 3 months of the scan in 9/32 patients. Of the 9 patients who were maintained on their current treatment regimen, 5 patients demonstrated subsequent disease progression at 3 (n=2), 5 (n=2), and 11 (n=1) months (mean TTP = 5.4 months, range 3-11 months). One patient remains stable at 16 months and 3 patients have insufficient follow-up. Therapy was changed immediately after the scan in the remaining 22 patients for various reasons including preference of the treating oncologists, treatment toxicities, increase in tumor markers, or clinical progression. Conclusions: MMTR+SDCT in patients with MBC predicted subsequent disease progression within 6 months in the majority of individuals. Oncologists commonly alter treatment regimen when faced with a report of MMTR+SDCT. Based on the observation of outcomes in patients who did not change therapy, this practice seems justified.

Non-accidental Paracetamol Poisoning in an Eleven Month-old Child

1983 ◽  
Vol 2 (2) ◽  
pp. 317-319 ◽  
Author(s):  
C.J. Taylor ◽  
A.M. Betts
Keyword(s):  
Case Report ◽  
Treatment Regimen ◽  
Current Treatment ◽  
Active Management ◽  
Accidental Poisoning ◽  
Paracetamol Poisoning ◽  
Current Treatment Regimen ◽  
Common Precipitant ◽  
A Current

1 Although accidental poisoning of children with drugs and chemicals is a common precipitant for admission to hospital, the possibility of deliberate poisoning as an extension of 'the battered baby syndrome' is rarely considered. 2 Most children admitted following accidental ingestions require little active management other than induction of emesis. Reports of relatively large overdoses in infancy are rare, and protocols for management of such cases largely untried. This case report demonstrates the successful application of a current treatment regimen to an infant who had ingested a substantial quantity of paracetamol.

Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: Results from a nationwide patient survey

2014 ◽  
Vol 43 (6) ◽  
pp. 745-750 ◽  
Author(s):  
Matthias Witt ◽  
Johanna Meier ◽  
Ariane Hammitzsch ◽  
Fabian Proft ◽  
Hendrik Schulze-Koops ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
Disease Burden ◽  
Patient Survey ◽  
Current Treatment ◽  
Sapho Syndrome ◽  
Current Treatment Regimen

scholarly journals Assessment and associated factors of suicidal behaviour among cancer patients visiting the oncology outpatient unit in Mekelle oncologic clinics, Tigray, Ethiopia: a cross−sectional study

2020 ◽  
Author(s):  
abreha Tsegay Gebreselassie ◽  
workua mekonen metekiya ◽  
birhane gebrehiwot beyene
Keyword(s):  
Cancer Patients ◽  
Treatment Regimen ◽  
Suicidal Behavior ◽  
Suicidal Behaviour ◽  
Associated Factors ◽  
Cross Sectional Study ◽  
Current Treatment ◽  
Sectional Study ◽  
Cross Sectional ◽  
Current Treatment Regimen

Abstract Background Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. According to estimates from the International Agency for Research on Cancer, there will be 17.0 million new cancer cases in 2018 worldwide. Depression, age, sex, divorced, and hopelessness are of most factors can patient with cancer result in suicidal behaviour. The purpose of this study is to identify and associated factors of suicidal behaviour among cancer patients in Mekelle, Ethiopia. Methods The cross-sectional study design was employed with a total of 345 study subjects in Mekelle, Ethiopia. Suicidal behaviour was measured by the Suicidal Behavior Questionnaire-Revised (SBQ-R) scale. Bivariate and multiple logistic regression analyses were performed to determine between the explanatory and outcome variables. Results The magnitude of suicidal behaviour was 20%. Previously suicidal attempt [AOR = 31.466, 95% CI (14.552, 68.042), P < 0.0001] was associated factor whereas no comorbid physical illness [AOR = .0.363, 95% (0. 164, 0.806)] and current treatment regimen (surgery, radiotherapy and palliative care) were significantly protective factors for suicidal behavior. Conclusion No comorbid physical illness, suicide attempt and current treatment regimen were significant factors of suicidal behaviour. Oncologic professionals should assess patient suicidal risk assessment routinely and every professional focuses on management besides the medication.

Current Treatment Strategies in Breast Cancer Brain Metastases

2019 ◽  
pp. 267-279
Author(s):  
Rupert Bartsch ◽  
Elisabeth Sophie Bergen ◽  
Karin Dieckmann ◽  
Anna Sophie Berghoff ◽  
Matthias Preusser
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Breast Cancer Brain Metastases

scholarly journals The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer

2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Kirollos Hanna, PharmD, BCPS, BCOP ◽  
Kelley Mayden, MSN, FNP, AOCNP
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Drug Market ◽  
Current Treatment ◽  
Major Barrier ◽  
Chemotherapy Drugs ◽  
Oral Formulations ◽  
Real World Evidence ◽  
Almost All ◽  
Oral Oncolytics

Almost all patients with breast cancer will eventually receive chemotherapy drugs, the majority of which are administered as IV infusions. Real-world evidence indicates that while current treatment paradigms vary considerably from guideline recommendations, there is an increasing trend towards a preference for oral oncolytics among patients with breast cancer. Recent data have shown that oral anticancer therapeutics represent 25% of the oncology drug market share and that there is a high demand for these agents. Therefore, oral formulations of chemotherapy agents such as paclitaxel are currently under development. Although oral oncolytics are associated with several advantages over conventional intravenous drugs, maintaining adherence to therapy is a major barrier in achieving improved outcomes with these agents. Advanced practitioners can facilitate improved adherence to oral oncolytics by integrating evidence into practice to support better education and communication strategies to address patient concerns, overcome key hurdles, and ultimately, empower patients.

Therapeutic Potential of Lymphoid Infiltrates in Breast Cancer

2021 ◽  
Vol 28 ◽  
Author(s):  
Xiao-Yang Chen ◽  
Puay Hoon Tan
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Immune System ◽  
Therapeutic Potential ◽  
Antibody Therapy ◽  
Tumour Microenvironment ◽  
Current Treatment ◽  
Adoptive Cell Transfer ◽  
Treatment Modalities ◽  
Patient Specific

: Despite diagnostic and therapeutic advances in breast cancer, it remains the most frequently diagnosed malignancy in females, with the highest cancer-related mortality rate in women globally. With an improved understanding of the complex interactions between breast cancer and the immune system, immunotherapy has shown great potential in clinical management, potentially adding to current treatment modalities. These immunotherapeutic approaches include adoptive cell transfer therapy, cancer vaccination, monoclonal antibody therapy, and oncolytic virus therapy. Depending on the immune cells and cytokines present, the tumour microenvironment (TME) can be immunosuppressive or favourable for mounting an immune response. Effector lymphocytes play an essential role during an anticancer immune response, but their activities can be suppressed by the hostile TME. Many studies have made good progress in the modulation of the immune response to allow the identification and elimination of tumour cells. However, the efficacy of these immunotherapies is patient-specific and highly dependent on the immunological profile of the tumour and its TME. This review will give an overview of breast cancer, the immune system as well as their complex relationship. Strategies and approaches that can harness the potential of immunotherapy that engages lymphocytes in the treatment of breast cancer, along with their current challenges, will also be discussed.

Sign in / Sign up

Export Citation Format

Share Document